The in-vitro activity of bicozamycin against anaerobic bacteria of clinical interest.
The in-vitro activity of bicozamycin (bicyclomycin, CGP 3543E; FR 1881), an oral antidiarrhoeal agent, was assessed against 389 clinical isolates and reference strains of anaerobic bacteria. The compound inhibited the majority of Gram-negative anaerobes at concentrations of 256 mg/l or less, but all of the test anaerobic cocci and 40 out of 43 strains of clostridia were resistant to this concentration, with MIC values usually in excess of 1024 mg/l. MBC values for bicozamycin against strains of Bacteroides fragilis were generally greatly in excess of MIC values.
D001421:Bacteria, Anaerobic / Q000187:drug effects*; D001424:Bacterial Infections / Q000382:microbiology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003470:Culture Media; D006089:Gram-Negative Anaerobic Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008826:Microbial Sensitivity Tests
D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003470:Culture Media; C024504:bicozamycin